Treatment-Resistant Depression across the Shrink Network.
When two adequate antidepressant trials haven't worked, the next-line options across the network.
Reviewed by Shariq Refai, MD, MBA
Treatment-resistant depression has a specific definition: the persistence of significant depressive symptoms after two or more adequate antidepressant trials. "Adequate" matters. It means sufficient dose for sufficient duration, usually six to eight weeks at target dose, with reasonable adherence. Many people who think they have treatment-resistant depression actually haven't had an adequate trial yet.
When the trials really have been adequate, the cluster is its own situation. The standard first-line approach (an SSRI, time, hope) has been tried and didn't work. The next steps include augmentation strategies, switching antidepressant classes, neurostimulation (TMS, ECT), rapid-acting treatments (ketamine, esketamine), and referral to a depression specialty clinic. Most cases respond to one of these. It just takes more attempts than the average primary care office is set up to manage.
Each site in the Shrink Network covers treatment-resistant depression from a different angle. Shrinkopedia provides the clinical reference. DepressionResource provides the Treatment-Resistant Depression Map. PsychiatryRx covers the augmentation strategies and rapid-acting treatments. shrinkMD provides the care option, including the specialist-level management that this cluster usually needs. This cluster page collects all seven layers.
Shrinkopedia
Treatment-Resistant Depression
The clinical encyclopedia entry. The definition (two adequate trials), the augmentation strategies, TMS, ketamine/esketamine, ECT, and the evidence for each.
Read on Shrinkopedia →DepressionResource
The Treatment-Resistant Depression Map
The visual cluster page. Adequate dose and duration, persistent anhedonia, augmentation, TMS, ketamine, ECT, specialist referral.
Open the Treatment-Resistant Depression Map →AnxietyResearch
STAR*D and the evidence for sequential antidepressant trials
The evidence layer. What the major treatment-resistant depression trials (STAR*D, others) actually found about sequencing and remission rates.
Open AnxietyResearch →PsychiatryRx
Augmentation, TMS, ketamine: the next-line options
The medication layer. Lithium augmentation, atypical antipsychotic augmentation, TMS, intranasal esketamine: what each does, the evidence, and the timelines.
Open PsychiatryRx →shrinQ
When the patterns persist through treatment
The pattern layer. Treatment-resistant depression often runs partly on cognitive and behavioral patterns that medication alone doesn't move. shrinQ addresses the pattern layer alongside medical treatment.
Open shrinQ →shrinkMD
Treatment-resistant depression care at shrinkMD
The care option. Telepsychiatry that includes augmentation management, the option of referring to TMS or ketamine specialists, and the sequential trial approach that this cluster usually requires.
Get care at shrinkMD →shariqrefai.com
On the depression that didn't respond
The reflective layer. Essays on what it means to keep trying treatments, what it takes to stay in care after the first attempts didn't work, and the recoveries that do eventually come.
Read essays →Treatment-resistant depression is one of the most under-recognized clusters in mental health, because the most common response to a partially-working first medication is to stay on it and hope. Naming the cluster as treatment-resistant unlocks the next-line options that actually move it. The cluster above is the network's coverage in one place, so the path from incomplete first response to the right next-line treatment is fully visible.